NeurAxis, Inc., a medical technology company, has achieved a significant milestone with the inclusion of its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology into newly released clinical practice guidelines. These guidelines, issued by a leading pediatric academic society, recommend PENFS for the treatment of Functional Abdominal Pain (FAP) in Irritable Bowel Syndrome (IBS). This development is expected to unlock large-scale insurance coverage for NeurAxis's flagship product, IB-Stim, and drive accelerated growth. The practice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition highlight PENFS as one of the top recommended therapies, marking it as the only FDA-cleared treatment for pediatric use. This achievement sets the stage for NeurAxis to expand its market presence and revenue generation in the United States, targeting an addressable market valued at over $3 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.